With the budget that reopened the government on November 13, 2026, ACLA scored a short term win in delaying PAMA cuts. I'll quote them below.
Washington, D.C. – The American Clinical Laboratory Association (ACLA) applauds the enactment of a short-term delay to payment cuts to the Medicare Clinical Laboratory Fee Schedule (CLFS) and data reporting requirements under the 2014 Protecting Access to Medicare Act (PAMA), included in the federal government funding package.
The provision delays these harmful policies through January 30, 2026.
Without this latest extension, laboratories would have faced a fourth round of cuts—up to 15 percent reductions on roughly 800 tests—along with burdensome reporting mandates beginning in [January 1] 2026.
##
“Now, Congress has a vital opportunity to prioritize enacting meaningful, permanent reform through the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act (H.R. 5269 / S. 2761).” [the President of ACLA] added. “ACLA is committed to working with lawmakers and key health care committees to advance the RESULTS Act and protect patient access to critical laboratory testing services nationwide.”
The RESULTS Act would modernize the CLFS rate-setting process by leveraging comprehensive, representative commercial market data while significantly reducing administrative burdens on laboratories and the Centers for Medicare & Medicaid Services.
##
See an October 30, 2025, two-page letter to both House and Senate.
https://www.acla.com/wp-content/uploads/2025/10/2025-RESULTS-Act_Provider-Letter-10.30.25.pdf
